Drug Profile
Research programme: memantine derivatives - NeuroMolecular Pharmaceuticals
Alternative Names: Memantine analogues - NeuroMolecularLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NeuroMolecular Pharmaceuticals
- Class Adamantanes; Organic bridged compounds
- Mechanism of Action Nitric oxide modulators; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders; Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 16 Jul 2016 No recent reports of development identified for research development in Neuropathic-pain in USA